Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Authors
Category Primary study
Year 2019
This article has no abstract
Epistemonikos ID: 983d25f62a79de8a72b408d8fd66949c1806a36d
First added on: Oct 05, 2021